keyword
MENU ▼
Read by QxMD icon Read
search

Clozapine

keyword
https://www.readbyqxmd.com/read/28101323/gabapentin-treatment-in-clozapine-induced-restless-legs-syndrome-two-cases-and-a-review-of-the-literature
#1
REVIEW
Vijaya Kumar, Ganesan Venkatasubramanian
Restless legs syndrome (RLS) is a neuro-sensorimotor disorder affecting 2-4% of adults. It is characterized by intense urges to move the legs, associated with unpleasant sensory disturbances in the legs occurring at rest and manifests mostly in the evening and night, relieved by movement. Diagnosis is primarily based on clinical presentation and the consensus criteria for the diagnosis have been established. Antipsychotics, the dopamine antagonists, have been reported to induce RLS. Dopamine agonists, the effective first-line treatment of RLS, carry the risk of inducing or worsening psychosis...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28096876/effectiveness-of-electroconvulsive-therapy-augmentation-on-clozapine-resistant-schizophrenia
#2
Hye Sung Kim, Se Hyun Kim, Nam Young Lee, Tak Youn, Jeoung Hyuk Lee, Seunghyun Chung, Yong Sik Kim, In Won Chung
OBJECTIVE: This retrospective case series study of the effectiveness of electroconvulsive therapy (ECT) augmentation on clozapine-resistant schizophrenia was conducted by EMR review. METHODS: Clozapine-resistance was defined as persistent psychotic symptoms despite at least 12 weeks of clozapine administration with blood levels over 350 ng/mL in order to rule out pseudo-resistance. Seven in-patients who were taking clozapine and treated with ECT were selected. We analyzed the psychopathology and subscales changed by ECT...
January 2017: Psychiatry Investigation
https://www.readbyqxmd.com/read/28096874/prevalence-of-metabolic-syndrome-in-patients-with-schizophrenia-in-korea-a-multicenter-nationwide-cross-sectional-study
#3
Jung Sun Lee, Jun Soo Kwon, Daeho Kim, Sung-Wan Kim, Jae-Jin Kim, Jong-Hoon Kim, Hee Jung Nam, Seunghyong Ryu, Il Ho Park, Suk Kyoon An, Hong-Seok Oh, Seunghee Won, Kanguk Lee, Kyu Young Lee, Seung-Hwan Lee, Yu Sang Lee, Jung-Seo Yi, Kyung Sue Hong, Yeon Ho Joo
OBJECTIVE: We designed a nationwide study with limited exclusion criteria to investigate the prevalence of metabolic syndrome (MetS) in Korea and its relationship with antipsychotic medications. METHODS: This multicenter, cross-sectional, and observational study included patients diagnosed with schizophrenia or schizoaffective disorder. Sixteen hospitals enrolled 845 patients aged 18 to 65 years prescribed any antipsychotic medication between August 2011 and August 2013...
January 2017: Psychiatry Investigation
https://www.readbyqxmd.com/read/28086761/is-treatment-resistant-schizophrenia-categorically-distinct-from-treatment-responsive-schizophrenia-a-systematic-review
#4
Amy L Gillespie, Ruta Samanaite, Jonathan Mill, Alice Egerton, James H MacCabe
BACKGROUND: Schizophrenia is a highly heterogeneous disorder, and around a third of patients are treatment-resistant. The only evidence-based treatment for these patients is clozapine, an atypical antipsychotic with relatively weak dopamine antagonism. It is plausible that varying degrees of response to antipsychotics reflect categorically distinct illness subtypes, which would have significant implications for research and clinical practice. If these subtypes could be distinguished at illness onset, this could represent a first step towards personalised medicine in psychiatry...
January 13, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28076667/effectiveness-of-antipsychotic-drugs-for-24-month-maintenance-treatment-in-first-episode-schizophrenia-evidence-from-a-community-based-real-world-study
#5
Chen Zhang, Mei-Juan Chen, Guo-Jun Wu, Zuo-Wei Wang, Shun-Zeng Rao, Yi Zhang, Zheng-Hui Yi, Wei-Min Yang, Ke-Ming Gao, Li-Sheng Song
OBJECTIVE: Maintenance treatment of schizophrenia with antipsychotic medications has become a standard for the prevention of psychotic relapse. However, little is known about the effectiveness of antipsychotic drugs for maintenance treatment in "real-world" populations with schizophrenia. We carried out a prospective study to assess the effectiveness of the most frequently prescribed antipsychotic drugs in the maintenance treatment of schizophrenia from 2 community settings. METHODS: This study was conducted from October 2011 to December 2014...
November 2016: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28074346/actively-negotiating-the-mind-body-divide-how-clozapine-treated-schizophrenia-patients-make-health-for-themselves
#6
Julia E H Brown, Simone Dennis
It is well recognised that antipsychotic treatments impact the whole body, not just the target area of the brain. For people with refractory schizophrenia on clozapine, the gold standard antipsychotic treatment in England and Australia, the separation of mental and physical regimes of health is particularly pronounced, resulting in multiple, compartmentalised treatment registers. Clinicians often focus on the mental health aspects of clozapine use, using physical indicators to determine whether treatment can continue...
January 10, 2017: Culture, Medicine and Psychiatry
https://www.readbyqxmd.com/read/28072646/clozapine-treatment-of-olanzapine-induced-tardive-dyskinesia-a-case-report
#7
Dinesh Sangroula, Inderpreet Virk, Wali Mohammad, David A Kahn
Tardive dyskinesias (TD) are serious, often irreversible side effects of dopamine blocking agents, most commonly first-generation antipsychotics. No definitive treatment exists, with different interventions showing inconsistent results. We report a case of TD presenting after 12 years of olanzapine therapy in a 66-year-old Hispanic male with paranoid schizophrenia. The TD symptoms were successfully treated within a few weeks by switching to clozapine. Two cases of olanzapine-induced TD treated with clozapine have previously been reported, but in those cases, the symptom onset was quicker, ranging from a few months to a few years after initiation of olanzapine therapy, and the treatment response was relatively slower...
January 2017: Journal of Psychiatric Practice
https://www.readbyqxmd.com/read/28071178/psychotropic-drugs-and-ventricular-repolarisation-the-effects-on-qt-interval-t-peak-to-t-end-interval-and-qt-dispersion
#8
Tiziano Acciavatti, Giovanni Martinotti, Mariangela Corbo, Eduardo Cinosi, Matteo Lupi, Fabrizio Ricci, Rosa Di Scala, Emilia D'Ugo, Viola De Francesco, Raffaele De Caterina, Massimo di Giannantonio
OBJECTIVE: We aimed to investigate in a clinical setting, the effects of different classes of psychotropic drugs on cardiac electrophysiological measures linked with an increased risk of sudden cardiac death. METHODS: We conducted a cross-sectional study in a population of 1059 psychiatric inpatients studying the effects of various psychotropic drugs on the T-peak to T-end (TpTe) interval, QT dispersion and QT interval. RESULTS: Methadone use showed a strong association with TpTe prolongation (odds ratio (OR)=12...
January 1, 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28071142/erratum
#9
(no author information available yet)
Lee J, Takeuchi H, Fervaha G, Sin GL, Foussias G, Agid O, Farooq S, Remington G. Subtyping schizophrenia by treatment response: antipsychotic development and the central role of positive symptoms. Can J Psychiatry. 2015;60(11):515-522. Original DOI: 10.1177/070674371506001107. In Table 2 of the above article, in "Proposed criteria for clozapine resistance" for "Current illness severity," the CGI-SCH positive was stated as "> 4" but it should be "CGI-SCH positive ≥ 4." The corrected table is below. [Table: see text]...
March 2016: Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie
https://www.readbyqxmd.com/read/28070497/clozapine-for-mitochondrial-psychosis
#10
Josef Finsterer, Sinda Zarrouk-Mahjoub
No abstract text is available yet for this article.
March 2017: Molecular Genetics and Metabolism Reports
https://www.readbyqxmd.com/read/28067751/efficacy-of-clozapine-on-dopamine-supersensitivity-psychosis-in-schizophrenia
#11
Yusuke Nakata, Nobuhisa Kanahara, Hiroshi Kimura, Hiroyuki Watanabe, Masaomi Iyo
Although the effectiveness of clozapine (CLZ) for patients with treatment-resistant schizophrenia (TRS) has been well established, its active mechanism has not been completely clarified. Several clinical studies showed that neuroleptic-induced dopamine supersensitivity psychosis (DSP) could be involved in the etiology of TRS. We preliminarily explored the possible beneficial effect of CLZ for dopamine supersensitivity schizophrenia. The present study is a case series. We followed 15 patients with DSP for about 2...
January 6, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28066016/thrombocytopenia-associated-with-olanzapine-a-case-report-and-review-of-literature
#12
Swapnajeet Sahoo, Himanshu Singla, M Spoorty, Pankaj Malhotra, Sandeep Grover
There is limited literature on olanzapine-associated thrombocytopenia. In this report, we present a case of a 32-year-old female, suffering from persistent delusional disorder who had thrombocytopenia (46,000/mm(3)) with the use of olanzapine 25 mg/day, 6 weeks after starting medication. Blood film did not reveal any evidence of any dysplastic cells, disturbance in the count of other cell lines, and autoimmune workup including antinuclear antibodies and anti-neutrophil cytoplasmic antibodies were found to be negative...
July 2016: Indian Journal of Psychiatry
https://www.readbyqxmd.com/read/28065233/optimal-treatment-strategies-of-clozapine-for-refractory-schizophrenia
#13
Yuan-Yuan Li, Yun-Shu Zhang, Jian Wang, Ke-Qing Li, Hong-Ying Wang
Objective To systematically evaluate the efficacy of clozapine combined with other antipsychotic drugs in the treatment of refractory schizophrenia. Methods We searched Medline, EMBASE, and China Biology Medicine databases in both English and Chinese for randomized controlled trials, quasi-randomization controlled trials, and clinical controlled trials concerning the combinations of clozapine with other antipsychotic drugs for refractory schizophrenia. Quality assessment and data extraction were conducted with the Cochrane collaboration's RevMan 5...
December 20, 2016: Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae
https://www.readbyqxmd.com/read/28064233/clozapine-associated-with-autoimmune-reaction-fever-and-low-level-cardiotoxicity-a-case-report
#14
Charilaos Gerasimou, Georgia Phaedra Vitali, George D Vavougios, Charalabos Papageorgiou, Athanasios Douzenis, Styliani I Kokoris, Ioannis Liappas, Emmanouil Rizos
BACKGROUND: Clozapine is a second-generation antipsychotic drug used in treatment-resistant schizophrenia. Fever induced by clozapine is a rather frequent side-effect which usually occurs in the first 4 weeks of treatment. Despite its effectiveness, there are potentially life-threatening adverse effects, such as cardiotoxicity. CASE REPORT: We present the case of a 31-year-old caucasian male with refractory schizophrenia who developed benign fever, increase of C-reactive protein and high troponin levels, without presenting any other signs to myocarditis, on the 13th day under clozapine treatment, which declined progressively upon discontinuation of the drug...
January 2017: In Vivo
https://www.readbyqxmd.com/read/28062471/pharmacological-guidelines-for-schizophrenia-a-systematic-review-and-comparison-of-recommendations-for-the-first-episode
#15
Dolores Keating, Stephen McWilliams, Ian Schneider, Caroline Hynes, Gráinne Cousins, Judith Strawbridge, Mary Clarke
OBJECTIVES: Clinical practice guidelines (CPGs) support the translation of research evidence into clinical practice. Key health questions in CPGs ensure that recommendations will be applicable to the clinical context in which the guideline is used. The objectives of this study were to identify CPGs for the pharmacological treatment of first-episode schizophrenia; assess the quality of these guidelines using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument; and compare recommendations in relation to the key health questions that are relevant to the pharmacological treatment of first-episode schizophrenia...
January 6, 2017: BMJ Open
https://www.readbyqxmd.com/read/28059928/clozapine-usage-increases-the-incidence-of-pneumonia-compared-with-risperidone-and-the-general-population-a-retrospective-comparison-of-clozapine-risperidone-and-the-general-population-in-a-single-hospital-over-25-months
#16
Zachary R Stoecker, Wales T George, Jeffrey B O'Brien, Jon Jancik, Eduardo Colon, Joseph J Rasimas
The aim of this study was to determine whether the incidence of pneumonia in patients taking clozapine was more frequent compared with those taking risperidone or no atypical antipsychotics at all before admission to a tertiary care medical center. This was a retrospective, case-matched study of 465 general medicine patients over a 25 month period from 1 July 2010 to 31 July 2012. Detailed electronic medical records were analyzed to explore the association between the use of two atypical antipsychotics and incidence of pneumonia...
January 4, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28057087/sleep-homeostatic-and-waking-behavioral-phenotypes-in-egr3-deficient-mice-associated-with-serotonin-receptor-5-ht2-deficits
#17
Janne Grønli, William C Clegern, Michelle A Schmidt, Rahmi S Nemri, Michael J Rempe, Amelia L Gallitano, Jonathan P Wisor
STUDY OBJECTIVE: The expression of the immediate early gene early growth response 3 (Egr3) is a functional marker of brain activity including responses to novelty, sustained wakefulness, and sleep. We examined the role of this gene in regulating wakefulness and sleep. METHODS: Electroencephalogram/electromyogram (EEG/EMG) were recorded in Egr3-/- and wild-type (WT) mice during 24 h baseline, 6 h sleep disruption and 6 h recovery. Serotonergic signaling was assessed with 6 h EEG/EMG recordings after injections of nonselective 5-HT2 antagonist (clozapine), selective 5-HT2 antagonists (5-HT2A; MDL100907 and 5-HT2BC; SB206553) and a cocktail of both selective antagonists, administered in a randomized order to each animal...
December 1, 2016: Sleep
https://www.readbyqxmd.com/read/28049887/evaluation-of-the-expression-profile-of-extrapyramidal-symptoms-due-to-antipsychotics-by-data-mining-of-japanese-adverse-drug-event-report-jader-database
#18
Eiji Kose, Kana Uno, Hiroyuki Hayashi
 Typical antipsychotics are easily expressed as adverse events such as extrapyramidal symptom (EPS). On the other hand, incidence of adverse events due to atypical antipsychotics is low. Therefore, currently, atypical antipsychotics are widely used to treat schizophrenia. However, it has been reported that there is no difference in the frequency of EPS in atypical and typical antipsychotics. This study aimed to evaluate the expression profile of EPS in atypical and typical antipsychotics treatment using the Japanese Adverse Drug Event Report (JADER) database...
2017: Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan
https://www.readbyqxmd.com/read/28038920/analysis-of-differential-gene-expression-mediated-by-clozapine-in-human-postmortem-brains
#19
Brian J Lee, Luigi Marchionni, Carrie E Andrews, Alexis L Norris, Leslie G Nucifora, Yeewen Candace Wu, Robert A Wright, Jonathan Pevsner, Christopher A Ross, Russell L Margolis, Akira Sawa, Frederick C Nucifora
Clozapine is the only medication indicated for treating refractory schizophrenia, due to its superior efficacy among all antipsychotic agents, but its mechanism of action is poorly understood. To date, no studies of human postmortem brain have characterized the gene expression response to clozapine. Therefore, we addressed this question by analyzing expression data extracted from published microarray studies involving brains of patients on antipsychotic therapy. We first performed a systematic review and identified four microarray studies of postmortem brains from antipsychotic-treated patients, then extracted the expression data...
December 27, 2016: Schizophrenia Research
https://www.readbyqxmd.com/read/28036099/can-drugs-induce-or-aggravate-sleep-apneas-a-case-non-case-study-in-vigibase-%C3%A2-the-who-pharmacovigilance-database
#20
Mélanie Linselle, Agnès Sommet, Emmanuelle Bondon-Guitton, Florence Moulis, Geneviève Durrieu, Justine Benevent, Vanessa Rousseau, Leila Chebane, Haleh Bagheri, François Montastruc, Jean-Louis Montastruc
The potential favorising role of drugs in Sleep Apnea Syndrome (SAS) is unknown. The present study investigates drugs associated with SAS in a pharmacovigilance database. SAS recorded as Adverse Drug Reactions (ADRs) in Vigibase(®) , the WHO pharmacovigilance database (more than 11 million reports), from 1978 to 2015 were selected. The risk of SAS reports was estimated using the case non-case method, with cases being SAS and non-cases all other recorded ADRs. During this 37-year period, 3,325 ADRs including the word SAS were registered (0...
December 30, 2016: Fundamental & Clinical Pharmacology
keyword
keyword
2685
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"